Adjuvant treatment of canine osteosarcoma with the human cytotoxic T- cell line TALL-104

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1868-1875

  Visonneau, Sophie ^a   Cesano, Alessandra ^a   Jeglum, K Ann ^b   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

^b Vet Oncol Serv and Res Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DOG; FEMALE; GAMMA IRRADIATION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIMB AMPUTATION; LIMB SALVAGE; MALE; NEUROPATHY; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; DOGS; FEMALE; HUMANS; MALE; NEOPLASM CIRCULATING CELLS; OSTEOSARCOMA; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032766925     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Knapp, D. W., and Waters, D. J. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol. Med. Today, 1: 8-11, 1997.
2. Berg, J. Canine osteosarcoma. Amputation and chemotherapy. Vet. Clin. N. Am. Small Anim. Pract., 26: 111-121, 1996.
3. Brodey, R. S. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J. Biol. Med., 52: 345-361, 1979.
4. LaRue, S. M., and Withrow, S. J. Tumors of the skeletal system. In: S. J. Withrow and E. G. MacEwen (eds.), Clinical Veterinary Oncology, pp. 234. Philadelphia: J. B. Lippincott, 1989.
5. MacEwen, E. G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev., 9: 125-136, 1990.
6. Withrow, S. J., Powers, B. E., Straw, R. C., and Wilkins, R. M. Comparative aspects of osteosarcoma: dog versus man. Clin. Orthopaed. Rel. Res., 270: 159-168, 1991.
7. Mauldin, G. N., Matus, R. E., Withrow, S. J., and Patnaik, A. K. Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J. Vet. Intern. Med., 2: 177-180, 1988.
8. Thompson, J. P., and Fugent, M. J. Evaluation of survival times after limb amputation, with or without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dog: 30 cases (1979-1990). J. Am. Vet. Med. Assoc., 200: 531-533, 1992.
9. Shapiro, W., Fossum, T. W., Kitchell, B. E., Couto, C. G., and Theiler, G. H. Use of cisplatin for the treatment of appendicular osteosarcoma in dogs. J. Am. Vet. Med. Assoc., 192: 507-511, 1988.
10. Straw, R. C., Withrow, S. J., Richter, S. L., Powers, B. E., Klein, M. K., Postorino, N. C., LaRue, S. M., Ogilvie, G. K., Vail, D. M., and Morrison, W. B. Amputation and cisplatin for treatment of canine osteosarcoma. J. Vet. Intern. Med., 5: 205-210, 1991.
11. MacEwen, E. G., and Kurzman, I. D. Canine osteosarcoma. Amputation and chemotherapy. Vet. Clin. N. Am. Small Anim. Pract., 26: 123-133, 1996.
12. Kurzman, I. D., MacEwen, E. G., Rosenthal, R. C., Fox, L. E., Keller, E. T., Helfhand, S. C., Vail, D. M., Dubielzig, R. R., Madewell, B. R., Rodriguez, C. O., Jr., Obrdovich, H., Fidel, J., and Rosenberg, M. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res., 1: 1595-1601, 1995.
13. O'Connor, R., Cesano, A., Kreider, B. L., Lange, B., Clark, S. C., Nowell, P. C., Finan, J., Rovera, G., and Santoli, D. Growth factor-dependent differentiation along the myeloid and lymphoid lineages in an immature acute T lymphocytic leukemia. J. Immunol., 145: 3779-3787, 1990.
14. Cesano, A., and Santoli, D. Two unique human leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity. Analysis and modulation of their lytic mechanisms. In Vitro Cell. Dev. Biol., 28A: 648-656, 1992.
15. Cesano, A., and Santoli, D. Inducible expression of granulocytemacrophage colony-stimulating factor, tumor necrosis factor-α, and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell. Dev. Biol., 28A: 657-662, 1992.
16. Cesano, A., Visonneau, S., Clark, S. C., and Santoli, D. Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-12. J. Immunol., 151: 2943-2957, 1993.
17. Visonneau, S., Cesano, A., Torosian, M. H., and Santoli, D. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient mice. Clin. Cancer Res., 3: 1491-1500, 1997.
18. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., Rovera, G., and Santoli, D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Investig., 94: 1076-1084, 1994.
19. Cesano, A., Visonneau, S., and Santoli, D. Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T-cell line. Cancer Res., 55: 96-101, 1995.
20. Cesano, A., Visonneau, S., and Santoli, D. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res., 18: 2289-2296, 1998.
21. Cesano, A., Visonneau, S., Rovera, G., and Santoli, D. Synergistic effects of Adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo. Anticancer Res., 17: 1887-1892, 1997.
22. Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., and Santoli, D. Anti-tumor efficacy of a human MHC non-restricted cytotoxic T cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res., 56: 4444-4452, 1996.
23. Cesano, A., Visonneau, S., Jeglum, K. A., Owen, J., Wilkinson, K., Carner, K., Reese, L., and Santoli, D. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res., 56: 3021-3029, 1996.
24. Visonneau, S., Cesano, A., Tran, T., Jeglum, K. A., and Santoli, D. Successful treatment of canine malignant histiocytosis with the human MHC non-restricted cytotoxic T cell line TALL-104. Clin. Cancer Res., 3: 1789-1797, 1997.
25. Cesano, A., Wortman, J. A., Pourdehnad, M., Visonneau, S., Mozley, D., Bhatnagar, A., Alavi, A., and Santoli, D. 1999. Effects of a multiple dose administration schedule on the biodistribution of TALL-104 cells in healthy dogs. Implications for adoptive cell therapy of cancer. Int. J. Oncol., 14: 233-244, 1999.
26. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, G. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.